Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 35 UKPDS: Tight glycaemic control reduces risk of micro- and macrovascular complications Risk reduction by lowering HbA1c by 1%-point -10 UKPDS 10 year follow-up: Legacy effect of tight glycaemic control Relative risk reduction of intensive vs. conventional treatment (%) Diabetes- related death Peripheral Myocardial Microvascular vascular infarction complications disease SU/Insulin treated patients Microvascular disease 1997 2007 25 24 Incidence risk (%) -20 -14% -21%* -30 -40 *p<0.0001 -50 Source: UKPDS, Stratton et al. BMJ 2000; vol. 321:405-12 changing diabetes® Diabetes-related death Myocardial infarction -37%* All-cause mortality -43%* 10 10 17 16 15 6 13 Statistically significant improvement Source: NEJM, vol. 359, Oct 2008 novo nordisk

View entire presentation